Symbols / INKT
INKT Chart
About
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 53.84M |
| Enterprise Value | 45.29M | Income | -12.36M | Sales | — |
| Book/sh | -2.94 | Cash/sh | 3.04 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -2.95 | PEG | — |
| P/S | — | P/B | -3.91 | P/C | — |
| EV/EBITDA | -3.70 | EV/Sales | — | Quick Ratio | 1.06 |
| Current Ratio | 1.08 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.01 | EPS next Y | -3.89 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-17 | ROA | -69.61% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.69M |
| Shs Float | 1.68M | Short Float | 1.92% | Short Ratio | 2.97 |
| Short Interest | — | 52W High | 76.00 | 52W Low | 6.34 |
| Beta | 0.34 | Avg Volume | 13.80K | Volume | 5.13K |
| Target Price | $39.00 | Recom | None | Prev Close | $11.34 |
| Price | $11.47 | Change | 1.15% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$39.00
Mean price target
2. Current target
$11.30
Latest analyst target
3. DCF / Fair value
$-18.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.30
Low
$35.00
High
$43.00
Mean
$39.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-15 | up | HC Wainwright & Co. | Neutral → Buy | $35 |
| 2025-07-15 | down | HC Wainwright & Co. | Buy → Neutral | $35 |
| 2025-07-14 | down | William Blair | Outperform → Market Perform | — |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-02-25 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-11-15 | main | Baird | Outperform → Outperform | $4 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-10-09 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-03-21 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2023-08-10 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-05-12 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-04-19 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-03-22 | main | Evercore ISI Group | — → Outperform | $3 |
| 2023-03-22 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2022-08-10 | init | HC Wainwright & Co. | — → Buy | $7 |
| 2022-01-24 | main | B. Riley Securities | — → Buy | $10 |
| 2021-11-09 | init | William Blair | — → Outperform | — |
| 2021-11-09 | init | Evercore ISI Group | — → Outperform | $30 |
- Precision Trading with Mink Therapeutics Inc. (INKT) Risk Zones - Stock Traders Daily Fri, 20 Feb 2026 07
- New IPF lung data: key immune cells depleted in advanced disease - Stock Titan ue, 03 Feb 2026 08
- MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily hu, 17 Jul 2025 07
- MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last week - Yahoo Finance Mon, 14 Jul 2025 07
- MiNK Therapeutics stock soars after cancer remission breakthrough - Investing.com Fri, 11 Jul 2025 07
- INKT's Investigational Cell Therapy Renders Testicular Cancer Patient Disease-free, Stock Soars - Nasdaq Fri, 11 Jul 2025 07
- MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week - simplywall.st Sun, 13 Jul 2025 07
- Why Is MiNK Therapeutics Stock (INKT) Up 190% Today? - TipRanks Fri, 11 Jul 2025 07
- MiNK Therapeutics: Moving Out Of The Hunt's Early Days (NASDAQ:INKT) - Seeking Alpha Mon, 14 Jul 2025 07
- MiNK Therapeutics Reports Promising Clinical Data and Leadership Expansion Amid Ongoing Development of iNKT Cell Therapies - Quiver Quantitative Fri, 14 Nov 2025 08
- Biotech breakthrough? INKT stock skyrockets 530% after cell therapy cures testicular cancer - The Economic Times Fri, 11 Jul 2025 07
- MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy - Stocktwits Fri, 11 Jul 2025 07
- MiNK Therapeutics announces board resignation amid public appointment - The Globe and Mail Sat, 03 Jan 2026 08
- Technical Reactions to INKT Trends in Macro Strategies - Stock Traders Daily Mon, 09 Feb 2026 08
- Trial tests cell therapy to prevent life-threatening transplant complication - Stock Titan hu, 08 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 31474 | 349991 | — | Stock Award(Grant) at price 11.12 per share. | BUELL JENNIFER | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 31474 | 349991 | — | Stock Award(Grant) at price 11.12 per share. | BUELL JENNIFER | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 1263 | 14007 | — | Stock Award(Grant) at price 11.09 per share. | WIINBERG ULF | Director | — | 2025-12-01 00:00:00 | D |
| 3 | 1612 | 17877 | — | Stock Award(Grant) at price 11.09 per share. | CORVESE BRIAN J | Director | — | 2025-12-01 00:00:00 | D |
| 4 | 1601 | 17755 | — | Stock Award(Grant) at price 11.09 per share. | RYAN BARBARA A. | Director | — | 2025-12-01 00:00:00 | D |
| 5 | 1466 | 16258 | — | Stock Award(Grant) at price 11.09 per share. | BEHNER PETER | Director | — | 2025-12-01 00:00:00 | D |
| 6 | 1218 | 13508 | — | Stock Award(Grant) at price 11.09 per share. | KADLEC ROBERT PETER | Director | — | 2025-12-01 00:00:00 | D |
| 7 | 1128 | 12510 | — | Stock Award(Grant) at price 11.09 per share. | HOLCOMB JOHN BRADLEY M.D. | Director | — | 2025-12-01 00:00:00 | D |
| 8 | 18229 | 279997 | — | Stock Award(Grant) at price 15.36 per share. | BUELL JENNIFER | Chief Executive Officer | — | 2025-09-09 00:00:00 | D |
| 9 | 18229 | 279997 | — | Stock Award(Grant) at price 15.36 per share. | BUELL JENNIFER | Chief Executive Officer | — | 2025-09-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.80M | -22.72M | -30.83M | -9.13M |
| TotalUnusualItems | -638.05K | 0.00 | -9.40M | |
| TotalUnusualItemsExcludingGoodwill | -638.05K | 0.00 | -9.40M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.78M | -22.46M | -27.99M | -30.21M |
| ReconciledDepreciation | 215.44K | 204.62K | 121.75K | 77.96K |
| EBITDA | -10.43M | -22.72M | -30.83M | -18.53M |
| EBIT | -10.65M | -22.92M | -30.95M | -18.61M |
| NetInterestIncome | 172.57K | 463.26K | 253.32K | -2.43M |
| InterestExpense | 2.43M | |||
| InterestIncome | 172.57K | 463.26K | 253.32K | |
| NormalizedIncome | -10.15M | -22.46M | -27.99M | -20.82M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.78M | -22.46M | -27.99M | -30.21M |
| TotalExpenses | 10.65M | 22.92M | 30.95M | 18.61M |
| TotalOperatingIncomeAsReported | -11.29M | -22.92M | -30.95M | -28.36M |
| DilutedAverageShares | 3.77M | 3.44M | 3.37M | 2.60M |
| BasicAverageShares | 3.77M | 3.44M | 3.37M | 2.60M |
| DilutedEPS | -2.86 | -6.54 | -8.30 | -11.60 |
| BasicEPS | -2.86 | -6.54 | -8.30 | -11.60 |
| DilutedNIAvailtoComStockholders | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncomeCommonStockholders | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncome | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncomeIncludingNoncontrollingInterests | -10.78M | -22.46M | -27.99M | -30.21M |
| NetIncomeContinuousOperations | -10.78M | -22.46M | -27.99M | -30.21M |
| PretaxIncome | -10.78M | -22.46M | -27.99M | -30.21M |
| OtherIncomeExpense | -307.13K | -10.00 | 2.70M | -9.17M |
| OtherNonOperatingIncomeExpenses | 330.92K | -10.00 | 2.70M | 221.92K |
| SpecialIncomeCharges | 0.00 | 355.51K | ||
| OtherSpecialCharges | -355.51K | |||
| GainOnSaleOfSecurity | -638.05K | -9.75M | ||
| NetNonOperatingInterestIncomeExpense | 172.57K | 463.26K | 253.32K | -2.43M |
| TotalOtherFinanceCost | -253.32K | 2.43M | ||
| InterestExpenseNonOperating | 2.43M | |||
| InterestIncomeNonOperating | 172.57K | 463.26K | 253.32K | |
| OperatingIncome | -10.65M | -22.92M | -30.95M | -18.61M |
| OperatingExpense | 10.65M | 22.92M | 30.95M | 18.61M |
| OtherOperatingExpenses | 9.75M | |||
| ResearchAndDevelopment | 6.34M | 15.49M | 23.12M | 13.97M |
| SellingGeneralAndAdministration | 4.31M | 7.43M | 7.83M | 4.64M |
| GeneralAndAdministrativeExpense | 4.31M | 7.43M | 7.83M | 4.64M |
| OtherGandA | 4.31M | 7.43M | 7.83M | 4.64M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.96M | 3.46M | 3.39M | 3.35M |
| ShareIssued | 3.96M | 3.46M | 3.39M | 3.35M |
| NetDebt | 347.57K | |||
| TotalDebt | 4.92M | |||
| TangibleBookValue | -19.59M | -18.06M | -401.30K | 23.78M |
| InvestedCapital | -14.66M | -18.06M | -401.30K | 23.78M |
| WorkingCapital | -1.97M | -7.80M | 7.72M | 23.17M |
| NetTangibleAssets | -19.59M | -18.06M | -401.30K | 23.78M |
| CommonStockEquity | -19.59M | -18.06M | -401.30K | 23.78M |
| TotalCapitalization | -14.66M | -18.06M | -401.30K | 23.78M |
| TotalEquityGrossMinorityInterest | -19.59M | -18.06M | -401.30K | 23.78M |
| StockholdersEquity | -19.59M | -18.06M | -401.30K | 23.78M |
| GainsLossesNotAffectingRetainedEarnings | -631.58K | -430.95K | -292.47K | -625.27K |
| OtherEquityAdjustments | -631.58K | -430.95K | -292.47K | -625.27K |
| RetainedEarnings | -144.18M | -133.40M | -110.94M | -82.95M |
| AdditionalPaidInCapital | 125.23M | 115.77M | 110.83M | 107.35M |
| CapitalStock | 40.00 | 35.00 | 339.00 | 335.00 |
| CommonStock | 40.00 | 35.00 | 339.00 | 335.00 |
| TotalLiabilitiesNetMinorityInterest | 25.31M | 22.61M | 21.87M | 16.47M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 18.35M | 11.21M | 9.19M | 0.00 |
| OtherNonCurrentLiabilities | 48.07K | 108.50K | ||
| DuetoRelatedPartiesNonCurrent | 13.42M | 11.16M | 9.08M | 0.00 |
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 4.92M | |||
| LongTermDebt | 4.92M | |||
| CurrentLiabilities | 6.96M | 11.40M | 12.68M | 16.47M |
| OtherCurrentLiabilities | 2.36M | 2.45M | 2.62M | 5.76M |
| PayablesAndAccruedExpenses | 4.60M | 8.95M | 10.06M | 10.70M |
| CurrentAccruedExpenses | 1.87M | 5.04M | 4.24M | 1.76M |
| Payables | 2.73M | 3.91M | 5.82M | 8.94M |
| DuetoRelatedPartiesCurrent | 0.00 | 5.95M | ||
| TotalTaxPayable | 0.00 | |||
| AccountsPayable | 2.73M | 3.91M | 5.82M | 3.00M |
| TotalAssets | 5.72M | 4.55M | 21.47M | 40.24M |
| TotalNonCurrentAssets | 732.93K | 953.98K | 1.07M | 606.60K |
| NetPPE | 732.93K | 953.98K | 1.07M | 606.60K |
| AccumulatedDepreciation | -524.64K | -495.64K | -283.68K | -168.60K |
| GrossPPE | 1.26M | 1.45M | 1.35M | 775.20K |
| OtherProperties | 1.26M | 1.45M | 1.35M | 775.20K |
| CurrentAssets | 4.99M | 3.60M | 20.40M | 39.63M |
| OtherCurrentAssets | 164.24K | 177.96K | 470.30K | 744.32K |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 246.60K | 53.11K | 298.67K | 1.76K |
| Receivables | 23.00K | |||
| TaxesReceivable | 23.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 4.58M | 3.37M | 19.64M | 38.89M |
| CashAndCashEquivalents | 4.58M | 3.37M | 19.64M | 38.89M |
| CashFinancial | 38.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.56M | -15.84M | -19.12M | -13.08M |
| RepurchaseOfCapitalStock | 0.00 | -477.64K | -157.19K | 0.00 |
| IssuanceOfDebt | 5.00M | 0.00 | 0.00 | 9.46M |
| IssuanceOfCapitalStock | 5.80M | 0.00 | 0.00 | 39.80M |
| CapitalExpenditure | -73.56K | -250.05K | -248.98K | |
| InterestPaidSupplementalData | 13.13K | 27.51K | 10.82K | 0.00 |
| EndCashPosition | 4.58M | 3.37M | 19.64M | 38.89M |
| BeginningCashPosition | 3.37M | 19.64M | 38.89M | 2.69M |
| EffectOfExchangeRateChanges | -54.70K | -25.25K | 19.39K | 16.90K |
| ChangesInCash | 1.26M | -16.24M | -19.27M | 36.18M |
| FinancingCashFlow | 10.82M | -407.17K | -155.60K | 49.26M |
| CashFlowFromContinuingFinancingActivities | 10.82M | -407.17K | -155.60K | 49.26M |
| ProceedsFromStockOptionExercised | 19.99K | 70.47K | 1.59K | 150.00 |
| NetCommonStockIssuance | 5.80M | -477.64K | -157.19K | 39.80M |
| CommonStockPayments | 0.00 | -477.64K | -157.19K | 0.00 |
| CommonStockIssuance | 5.80M | 0.00 | 0.00 | 39.80M |
| NetIssuancePaymentsOfDebt | 5.00M | 0.00 | 0.00 | 9.46M |
| NetShortTermDebtIssuance | 9.46M | |||
| ShortTermDebtIssuance | 9.46M | |||
| NetLongTermDebtIssuance | 5.00M | 0.00 | 0.00 | 9.46M |
| LongTermDebtIssuance | 5.00M | 0.00 | 0.00 | 9.46M |
| InvestingCashFlow | 0.00 | -73.56K | -250.05K | -248.98K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -73.56K | -250.05K | -248.98K |
| NetPPEPurchaseAndSale | 0.00 | -73.56K | -250.05K | -248.98K |
| PurchaseOfPPE | 0.00 | -73.56K | -250.05K | -248.98K |
| OperatingCashFlow | -9.56M | -15.76M | -18.87M | -12.83M |
| CashFlowFromContinuingOperatingActivities | -9.56M | -15.76M | -18.87M | -12.83M |
| ChangeInWorkingCapital | 459.73K | 2.90M | 8.77M | 3.74M |
| ChangeInOtherWorkingCapital | 2.23M | 2.54M | 2.98M | 3.47M |
| ChangeInPayablesAndAccruedExpense | -1.58M | 107.57K | 6.09M | -224.65K |
| ChangeInAccruedExpense | -393.77K | 2.03M | 3.42M | -72.61K |
| ChangeInPayable | -1.18M | -1.92M | 2.66M | -152.04K |
| ChangeInAccountPayable | -1.18M | -1.92M | 2.66M | -152.04K |
| ChangeInPrepaidAssets | -194.17K | 245.59K | -296.94K | 488.75K |
| OtherNonCashItems | 717.49K | -2.79M | 12.18M | |
| StockBasedCompensation | 1.81M | 3.86M | 3.03M | 1.74M |
| DepreciationAmortizationDepletion | 215.44K | 204.62K | 121.75K | 77.96K |
| DepreciationAndAmortization | 215.44K | 204.62K | 121.75K | 77.96K |
| Depreciation | 215.44K | 204.62K | 121.75K | 77.96K |
| OperatingGainsLosses | -1.97M | -266.78K | -2.79M | -355.51K |
| GainLossOnSaleOfBusiness | -185.35K | 0.00 | ||
| NetIncomeFromContinuingOperations | -10.78M | -22.46M | -27.99M | -30.21M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for INKT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|